BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...By Jeff Cranmer, Executive Editor NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series...
...included undisclosed institutional investors, VCs and KOSDAQ-listed companies.TARGETSPD-1 (PDCD1; CD279) - Programmed cell death 1 Jeff Cranmer Venrock Artiva Biotherapeutics Inc. Roivant...
BioCentury | Feb 5, 2021
Management Tracks

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

...in recent months that will take several years to bear fruit. Last month, Merck partnered with Artiva Biotherapeutics Inc....
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

...teams up with Artiva for CAR-NK cells against solid tumorsMerck & Co. Inc. (NYSE:MRK) partnered with Artiva Biotherapeutics Inc....
...P2X7) – Purinergic receptor P2X ligand-gated ion channel 7 BC Staff Quellis Biosciences Inc. Eli Lilly and Co. Asahi Kasei Artiva Biotherapeutics Inc. Bellicum...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...are more likely to mediate antibody-dependent cellular cytotoxicity. Artiva Biotherapeutics Inc.’s...
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...Korean company GC LabCell -- including one program due to enter the clinic this year. Artiva Biotherapeutics Inc....
...capital, while not required or essential, would be nice to have,” Farrell said. COMPANY PROFILE Artiva Biotherapeutics Inc....
...EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos, Associate Editor Green Cross LabCell Corp. GC Pharma Artiva Biotherapeutics Inc. AB-101 AB-201 AB-202 NK...
Items per page:
1 - 5 of 5
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...By Jeff Cranmer, Executive Editor NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series...
...included undisclosed institutional investors, VCs and KOSDAQ-listed companies.TARGETSPD-1 (PDCD1; CD279) - Programmed cell death 1 Jeff Cranmer Venrock Artiva Biotherapeutics Inc. Roivant...
BioCentury | Feb 5, 2021
Management Tracks

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

...in recent months that will take several years to bear fruit. Last month, Merck partnered with Artiva Biotherapeutics Inc....
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

...teams up with Artiva for CAR-NK cells against solid tumorsMerck & Co. Inc. (NYSE:MRK) partnered with Artiva Biotherapeutics Inc....
...P2X7) – Purinergic receptor P2X ligand-gated ion channel 7 BC Staff Quellis Biosciences Inc. Eli Lilly and Co. Asahi Kasei Artiva Biotherapeutics Inc. Bellicum...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...are more likely to mediate antibody-dependent cellular cytotoxicity. Artiva Biotherapeutics Inc.’s...
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...Korean company GC LabCell -- including one program due to enter the clinic this year. Artiva Biotherapeutics Inc....
...capital, while not required or essential, would be nice to have,” Farrell said. COMPANY PROFILE Artiva Biotherapeutics Inc....
...EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos, Associate Editor Green Cross LabCell Corp. GC Pharma Artiva Biotherapeutics Inc. AB-101 AB-201 AB-202 NK...
Items per page:
1 - 5 of 5